Your browser does not support the NLM PubReader view.
Go to this page to see a list of supported browsers
or return to the
regular view.

Page 0 of 0

NCBI Bookshelf

Home Browse All Titles Share on Facebook Share on Twitter

Table of Content

Health Technology Assessment Title Information Table of Contents Page

Settings

Switch to classic view PDF (1.8M)Print View

Help

Help Send us feedback About PubReader

✘

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Plain English summary
Scientific summary
Chapter 1. Background
Chapter 2. Definition of the decision problem
Chapter 3. Assessment of clinical effectiveness
Chapter 4. Evidence synthesis to inform the relative efficacy of the interventions
Chapter 5. Assessment of existing cost-effectiveness evidence
Chapter 6. Independent economic assessment
Chapter 7. Assessment of factors relevant to the NHS and other parties
Chapter 8. Discussion
Chapter 9. Conclusions
Acknowledgements
References
Appendix 1. Search strategies
Appendix 2. Summary of included records
Appendix 3. List of excluded studies with reasons for exclusion
Appendix 4. Evidence synthesis modelling, software and WinBUGS code
Appendix 5. Studies excluded from the network meta-analyses
Appendix 6. Evidence synthesis: fixed-effect model results
Appendix 7. Consistency assessment
Appendix 8. Additional cost-effectiveness results
Appendix 9. Adalimumab risk-of-bias assessment for trial extension periods
Appendix 10. Etanercept risk-of-bias assessment for trial extension periods
Appendix 11. Ustekinumab risk-of-bias assessment for trial extension periods
Appendix 12. Risk-of-bias assessment for observational multiple biological therapy studies
Glossary
List of abbreviations